Shanghai Pharma(601607) 证券之星·2025-03-27 13:11Core Viewpoint - The supervisory board of Shanghai Pharmaceuticals has approved the 2024 annual report, confirming its compliance with legal and regulatory requirements, and reflecting the company's operational and financial status accurately [1][2]. Group 1: Annual Report Review - The supervisory board conducted a thorough review of the 2024 annual report, affirming that the preparation and review processes adhered to all relevant laws, regulations, and internal management systems [2]. - The content and format of the 2024 annual report meet the requirements set by the China Securities Regulatory Commission and the Shanghai Stock Exchange, accurately reflecting the company's operational management and financial condition [2]. Group 2: Stock Option Plan - The board agreed to cancel 2,147,930 stock options from the third exercise period and 523,815 stock options from the second exercise period of the 2019 A-share stock option incentive plan that had not been exercised [2]. - The decision regarding the cancellation of stock options will also be submitted for approval at the company's shareholders' meeting [2]. Group 3: Dividend Distribution - A proposal regarding the distribution of cash dividends for the 2024 fiscal year was discussed, with one supervisor expressing concern that the total cash dividends distributed were relatively low compared to the net profit attributable to shareholders [2]. - The proposal for dividend distribution will be presented at the upcoming shareholders' meeting for further deliberation [2].